Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Lung Neoplasms 51Leukemia, Myeloid, Acute 45Neoplasm Metastasis 43Carcinoma, Non-Small-Cell Lung 37Breast Neoplasms 37Prostatic Neoplasms 30Multiple Myeloma 30Colorectal Neoplasms 27Pancreatic Neoplasms 26Melanoma 23Carcinoma, Renal Cell 23Ovarian Neoplasms 21Lymphoma 20Burkitt Lymphoma 19Triple Negative Breast Neoplasms 18Myelodysplastic Syndromes 18Leukemia, Lymphocytic, Chronic, B-Cell 18Lymphoma, Large B-Cell, Diffuse 17Urinary Bladder Neoplasms 16Precursor Cell Lymphoblastic Leukemia-Lymphoma 16Squamous Cell Carcinoma of Head and Neck 14Glioblastoma 14Fallopian Tube Neoplasms 14Carcinoma, Hepatocellular 14Oropharyngeal Neoplasms 13Glioma 13Sarcoma 12Mouth Neoplasms 12Carcinoma 12Astrocytoma 12

Interventions

lutetium Lu 177 dotatate 1cabozantinib 1Sunitinib 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Metastatic Digestive System Neuroendocrine Tumor G1 × Specimen Handling × 90 days × Clear all
NCT05773274 2026-06-03

Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial

National Cancer Institute (NCI)

Phase 2 Recruiting
100 enrolled
EndocrineNET

Metastatic Digestive System Neuroendocrine Tumor G1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡